Market news

Palvella Therapeutics advances QTORIN rapamycin for microcystic lymphatic malformations with strong Phase 3 data. Read more on PVLA stock here.

Palvella Therapeutics (PVLA) said Monday that it has received a third year of grant funding from the

Tipranks Press Release.

Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, research, and academic experience Longstanding Palvella clinical collaborator and QTORIN™ trial investigator brings deep understanding of the unmet needs in serious, rare skin diseases including vascular anomalies Dr. Treat to lead medical strategy as Palvella moves QTORIN™ rapamyci

WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in two upcoming healthcare investor c

Detailed price information for Protagonist Therapeutics Inc (PTGX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Palvella Therapeutics (PVLA) said Monday it has completed the rolling submission of a new drug appli

Palvella (PVLA) advances QTORIN rapamycin with Phase 3 SELVA data and a rolling NDA. Read here for a detailed investment analysis.

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Ge

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

Moby summary of Palvella Therapeutics, Inc.'s Q2 2026 earnings call

Palvella Therapeutics Inc (PVLA) reports robust QTORIN rapamycin results, a successful $230M capital raise, and on-track NDA submission for microcystic lymphatic malformations.

Palvella Therapeutics (NASDAQ:PVLA) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access

First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for a planned standalone U.S. commercial launch of QTORIN™ rapamycin for microcystic lymphatic malformations in the first half of 2027, if approved Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for the fourth quarter of 2026 Initiation of P

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half of 2026, with potential FDA approval targeted for the first half of 2027. The company has submitte

Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential...

WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that it will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Palvella manag

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

Palvella Therapeutics Inc. (NASDAQ:PVLA) is one of the 10 affordable biotech stocks to buy right now. On June 29, Palvella Therapeutics Inc. (NASDAQ:PVLA) disclosed that it filed the initial module of its New Drug Application with the FDA for approval of QTORIN 3.9% rapamycin anhydrous gel. QTORIN is used to treat microcystic lymphatic malformations. The […]